Diurnal Group plc, the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, will be presenting research findings on the treatment and management of congenital adrenal hyperplasia (CAH) at this year's European Congress of Endocrinology, which takes place 21-24 May 2022 in Milan, Italy. Over the four-day meeting, the following topics will be presented: Findings in fertility inCAH patients on Modified-Release Hydrocortisone Capsules (MR-HC, Efmody®). Findings on control of CAH on MR-HC. The burden of illness associated with adolescent and adult CAH. Literature review onsupraphysiological glucocorticoiddosing in CAH. MR-HC effects on mineralocorticoid requirements. CAH occurs when the production of cortisol from the adrenal gland is limited due to a genetic deficiency. CAH is associated with over-production of male sex hormones resulting in ambiguous genitalia at birth, precocious sexual development, infertility in men and women, and increased mortality through adrenal crisis. Around 450,000 people globally are estimated to be living with a CAH disorder yet there is no standard treatment. Instead, a variety of steroids are used but data shows around two thirds of people living with CAH still have problems with disease control.